Flash Finance

Gujarat Themis Biosyn LimitedGUJTHEMCorporate

Pharmaceuticals Latest results: Jun 2026 3 quarters of data
Consolidated Standalone
₹373.40
MCap ₹4,860 Cr
Gujarat Themis Biosyn Limited — Stock analysis & AI research Gujarat Themis Biosyn Limited — Multibagger AI analysis Gujarat Themis Biosyn Limited — Seasonality — best & worst months Gujarat Themis Biosyn Limited — Technical indicators & charts Gujarat Themis Biosyn Limited — Technical setup — score, trend, support & resistance Gujarat Themis Biosyn Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Interest Coverage Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹44 Cr
Sales · Jun 2026
+21.6% YoY
₹21 Cr
Operating Profit · Jun 2026
+48.5% YoY
47.5%
OPM % · Jun 2026
+22.1% YoY
₹11 Cr
Net Profit · Jun 2026
+23.0% YoY
₹1.02
EPS · Jun 2026
+22.9% YoY

📝 Gujarat Themis Biosyn Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Gujarat Themis Biosyn Limited reported revenue of ₹44 crore for the quarter ended June 2026 (Q1 FY27), up 21.6% from ₹36 crore in the same quarter last year, and down 0.5% sequentially over the March 2026 quarter.

Net profit rose 23.0% year-on-year to ₹11 crore, from ₹9 crore. Earnings per share (EPS) came in at ₹1.02.

Operating profit stood at ₹21 crore — an operating margin (OPM) of 47.5%, compared with 38.9% in the year-ago quarter.

Valuation snapshot

At the current price of ₹373.40, GUJTHEM has a market capitalisation of ₹4,860 crore.

Within the Pharmaceuticals industry, it is the 3rd-largest of the 82 companies we track by market value.

Shareholding pattern

As of Aug 2026, promoters held 59.33%, foreign institutional investors (FIIs) 4.93%, domestic institutional investors (DIIs) 13.79%, public shareholders 21.95% of Gujarat Themis Biosyn Limited.

Promoter holding slipped from 70.86% to 59.33% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹4,860 Cr
Current Price ?
₹373.4
P/E ?
N/A
Industry P/E ?
22.40
P/B ?
N/A
P/S ?
N/A
P/FCF ?
N/A
Enterprise Value ?
N/A
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
N/A
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
N/A
EPS (TTM) ?
N/A
ROCE ?
N/A
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹44 Cr
PAT — latest qtr ?
₹11 Cr
YoY qtr sales growth ?
21.6%
YoY qtr profit growth ?
23.0%
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
N/A
Debt to Equity ?
N/A
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
59.33%
Change in promoter holding ?
-11.53%
Pledged percentage ?
N/A
Market
Return 3 months ?
1.0%
Return 6 months ?
17.0%

🗓️ Quarterly results (3 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Jun 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 364444 +21.6% -0.5%
Operating Profit 141921 +48.5% +9.4%
Other Income 010 — -86.8%
Interest 022 — -10.7%
Depreciation 244 +98.6% -0.7%
Profit Before Tax 121415 +26.4% +8.3%
Net Profit 91111 +23.0% +0.6%
EPS 0.831.001.02 +22.9% +2.0%
OPM % 38.9% 43.2% 47.5% +22.1% +10.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

👥 Shareholding (latest 2 periods)

Metric Jun 2026Aug 2026 % Chg
Promoters 70.86%59.33% -16.3%
FIIs 1.77%4.93% +178.5%
DIIs 1.18%13.79% +1068.6%
Public 26.19%21.95% -16.2%
No. of Shareholders 27,01026,899 -0.4%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUDEEPPHRM Sudeep Pharma ₹1,033.30 11,671 63.3 675 184 34.6% 27.3% — — 26.6% 30.9%
2 SPARC Sun Pharma ₹185.08 6,006 3.8 1,909 1,584 84.7% 83.0% 2512.3% 553.9% 314.1% 59.9%
3 GUJTHEM Gujarat Themis ₹412.60 5,370 92.3 173 48 47.3% 27.8% 8.6% -6.1% 21.6% 23.0%
4 539997 Kwality Pharmaceuticals ₹2,652.10 3,525 34.0 553 81 24.4% 14.6% 35.7% 71.8% 46.3% 113.5%
5 524632 Shukra Pharmaceuticals ₹80.95 2,403 99.9 75 36 65.0% 48.2% 74.0% 130.1% 336.4% 1359.2%
6 FERMENTA Fermenta Biotech ₹475.00 1,362 21.4 501 64 18.9% 12.7% — — -17.9% -30.6%
7 506414 Fermenta Biotech ₹552.60 1,313 27.2 511 59 17.6% 11.5% 11.9% -6.6% -10.4% -56.7%
8 AHCL Anlon Healthcare ₹20.20 1,074 — — — — — — — 163.0% 133.3%
9 541096 Bharat Parenterals ₹1,525.00 1,062 — 323 -30 3.3% -9.3% 1.5% 37.5% -19.2% -309.6%
10 540737 Shree Ganesh ₹796.30 855 66.2 99 15 31.4% 15.6% 0.7% -23.0% -41.8% -67.5%
11 AMANTA Amanta Healthcare ₹197.75 768 52.5 291 15 20.4% 5.0% — — 5.4% -5.6%
12 539730 Fredun Pharmaceuticals ₹827.85 611 10.3 747 44 14.7% 5.9% 40.1% 90.0% 90.2% 88.1%
13 500422 Transchem Ltd-$ ₹38.00 474 10.8 — 4 — — -100.0% -17.8% -100.0% 186.3%
14 HALEOSLABS Haleos Labs ₹1,525.00 461 21.0 324 15 12.6% 4.7% -3.2% -4.9% -11.6% -58.0%
15 524731 Jenburkt Pharmaceuticals ₹865.75 404 11.6 170 33 23.6% 19.4% 11.8% 6.1% -1.4% -26.4%
16 543616 Trident Lifeline ₹279.85 364 14.0 134 24 24.6% 17.9% — — 42.6% 44.2%
17 512600 Astal Laboratories ₹75.00 308 32.3 170 10 8.8% 5.7% 142.9% -9.0% 56.0% 77.4%
18 524828 BDH Industries ₹336.80 300 16.6 100 12 15.3% 11.7% 44.3% 16.6% 20.2% 48.8%
19 500009 Ambalal Sarabhai ₹38.73 297 21.9 206 14 7.1% 6.6% 3.1% 261.1% 8.0% -51.6%
20 532039 Zenotech Laboratories ₹64.90 263 — 45 -3 17.0% -5.6% 1.3% -119.2% 10.1% -146.0%
21 531739 Gennex Laboratories ₹13.87 255 19.0 183 21 14.4% 11.3% 24.9% 15.5% 16.6% -6.9%
22 524790 Everest Organics ₹159.20 252 29.4 191 5 10.3% 2.8% 23.0% 527.7% -10.0% -21.1%
23 530163 Kerala Ayurveda ₹310.20 225 — 125 -26 -14.9% -20.8% 9.0% -16.8% -21.3% -477.8%
24 531569 Sanjivani Paranteral ₹199.95 214 32.7 66 7 15.3% 11.3% -7.6% -14.4% 8.8% 32.7%
25 524636 Oxygenta Pharmaceutical ₹32.25 195 — 135 -14 -5.9% -10.1% 3.3% -70.8% 144.5% 65.6%
❓ Frequently asked questions
What was Gujarat Themis Biosyn Limited's revenue in Q1 FY27?
Gujarat Themis Biosyn Limited reported revenue of ₹44 crore for the quarter ended June 2026 (Q1 FY27), up 21.6% from ₹36 crore in the same quarter last year, and down 0.5% sequentially over the March 2026 quarter.
What was Gujarat Themis Biosyn Limited's net profit in Q1 FY27?
Net profit rose 23.0% year-on-year to ₹11 crore, from ₹9 crore. Earnings per share (EPS) came in at ₹1.02.
What is GUJTHEM's market capitalisation and P/E ratio?
At the current price of ₹373.40, GUJTHEM has a market capitalisation of ₹4,860 crore.
Who owns Gujarat Themis Biosyn Limited? (shareholding pattern)
As of Aug 2026, promoters held 59.33%, foreign institutional investors (FIIs) 4.93%, domestic institutional investors (DIIs) 13.79%, public shareholders 21.95% of Gujarat Themis Biosyn Limited.
TTM ends N/A. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI